News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
713,734 Results
Type
Article (42289)
Company Profile (436)
Press Release (671009)
Multimedia
Podcasts (77)
Webinars (13)
Section
Business (208728)
Career Advice (2021)
Deals (36005)
Drug Delivery (104)
Drug Development (83572)
Employer Resources (173)
FDA (16426)
Job Trends (15094)
News (352774)
Policy (33077)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (5)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (8)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (2)
Academia (2643)
Accelerated approval (6)
Adcomms (24)
Allergies (84)
Alliances (50949)
ALS (93)
Alzheimer's disease (1425)
Antibody-drug conjugate (ADC) (135)
Approvals (16413)
Artificial intelligence (261)
Autoimmune disease (25)
Automation (16)
Bankruptcy (372)
Best Places to Work (11841)
BIOSECURE Act (19)
Biosimilars (105)
Biotechnology (330)
Bladder cancer (68)
Brain cancer (26)
Breast cancer (279)
Cancer (2201)
Cardiovascular disease (182)
Career advice (1688)
Career pathing (30)
CAR-T (152)
Cell therapy (429)
Cervical cancer (19)
Clinical research (67699)
Collaboration (859)
Compensation (526)
Complete response letters (24)
COVID-19 (2644)
CRISPR (42)
C-suite (242)
Cystic fibrosis (105)
Data (2122)
Decentralized trials (2)
Denatured (28)
Depression (49)
Diabetes (267)
Diagnostics (6414)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (126)
Drug pricing (106)
Drug shortages (26)
Duchenne muscular dystrophy (99)
Earnings (87653)
Editorial (39)
Employer branding (21)
Employer resources (147)
Events (115616)
Executive appointments (724)
FDA (17653)
Featured Employer (54)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (775)
Gene editing (109)
Generative AI (20)
Gene therapy (313)
GLP-1 (742)
Government (4498)
Grass and pollen (4)
Guidances (51)
Healthcare (19143)
Huntington's disease (24)
IgA nephropathy (27)
Immunology and inflammation (126)
Indications (29)
Infectious disease (2787)
Inflammatory bowel disease (140)
Inflation Reduction Act (11)
Influenza (51)
Intellectual property (94)
Interviews (311)
IPO (16781)
IRA (43)
Job creations (3700)
Job search strategy (1434)
Kidney cancer (10)
Labor market (38)
Layoffs (491)
Leadership (17)
Legal (7985)
Liver cancer (73)
Lung cancer (317)
Lymphoma (148)
Machine learning (5)
Management (58)
Manufacturing (303)
MASH (67)
Medical device (13506)
Medtech (13511)
Mergers & acquisitions (19746)
Metabolic disorders (703)
Multiple sclerosis (79)
NASH (19)
Neurodegenerative disease (97)
Neuropsychiatric disorders (33)
Neuroscience (1978)
NextGen: Class of 2025 (6755)
Non-profit (4547)
Northern California (2613)
Now hiring (39)
Obesity (381)
Opinion (223)
Ovarian cancer (75)
Pain (85)
Pancreatic cancer (82)
Parkinson's disease (153)
Partnered (21)
Patents (230)
Patient recruitment (105)
Peanut (47)
People (58633)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21265)
Phase II (29874)
Phase III (22094)
Pipeline (1157)
Policy (141)
Postmarket research (2601)
Preclinical (9079)
Press Release (67)
Prostate cancer (103)
Psychedelics (37)
Radiopharmaceuticals (262)
Rare diseases (398)
Real estate (6014)
Recruiting (66)
Regulatory (22692)
Reports (46)
Research institute (2415)
Resumes & cover letters (351)
Rett syndrome (4)
RNA editing (4)
RSV (42)
Schizophrenia (74)
Series A (137)
Series B (89)
Service/supplier (11)
Sickle cell disease (57)
Southern California (2257)
Special edition (17)
Spinal muscular atrophy (152)
Sponsored (30)
Startups (3761)
State (2)
Stomach cancer (14)
Supply chain (68)
Tariffs (32)
The Weekly (47)
United States (22983)
Vaccines (692)
Venture capitalists (43)
Weight loss (252)
Women's health (37)
Worklife (16)
Date
Today (196)
Last 7 days (573)
Last 30 days (2534)
Last 365 days (33819)
2025 (10016)
2024 (36301)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32347)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (736)
Alabama (57)
Alaska (7)
Arizona (238)
Arkansas (14)
Asia (39213)
Australia (6527)
California (6036)
Canada (1977)
China (512)
Colorado (265)
Connecticut (278)
Delaware (141)
Europe (85664)
Florida (879)
Georgia (203)
Idaho (57)
Illinois (537)
India (25)
Indiana (309)
Iowa (11)
Japan (159)
Kansas (105)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (889)
Massachusetts (4590)
Michigan (218)
Minnesota (389)
Mississippi (2)
Missouri (81)
Montana (29)
Nebraska (25)
Nevada (60)
New Hampshire (66)
New Jersey (1711)
New Mexico (30)
New York (1708)
North Carolina (1016)
North Dakota (7)
Northern California (2613)
Ohio (202)
Oklahoma (14)
Oregon (38)
Pennsylvania (1344)
Puerto Rico (11)
Rhode Island (33)
South America (1110)
South Carolina (21)
South Dakota (1)
Southern California (2257)
Tennessee (101)
Texas (899)
Utah (177)
Virginia (145)
Washington D.C. (63)
Washington State (563)
West Virginia (3)
Wisconsin (53)
713,734 Results for "diamedica therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results
March 17, 2025
·
15 min read
Press Releases
DiaMedica Therapeutics Appoints Daniel J. O’Connor to the Board of Directors
February 24, 2025
·
3 min read
Press Releases
DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025
March 12, 2025
·
1 min read
BioMidwest
DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement
DiaMedica Therapeutics Inc. today announced the closing of its previously announced $11.8 million private placement to accredited investors.
July 1, 2024
·
9 min read
Press Releases
DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 10, 2025
·
1 min read
BioMidwest
DiaMedica Therapeutics Announces $11.8 Million Private Placement
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced that it has entered into definitive agreements to sell its common shares in a private placement with accredited investors.
June 26, 2024
·
8 min read
BioMidwest
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia.
June 26, 2024
·
13 min read
Press Releases
DiaMedica Therapeutics Announces Publication of DM199’s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke
February 20, 2025
·
7 min read
Business
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the quarter ended March 31, 2024.
May 8, 2024
·
14 min read
Drug Development
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced the first patient being dosed in DiaMedica’s relaunch of its pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the treatment of acute ischemic stroke.
April 17, 2024
·
7 min read
1 of 71,374
Next
